# Chronic administration of a cannabis-derived mixture at an antihyperalgesic dose does not significantly enhance hepatotoxicity or the development of metabolic dysfunction-associated steatohepatitis in male mice

**Authors:** Kim B. Pedersen, Tomislav Jelesijevic, Tamara M. Morris, Sarah M. Melton, Ashley S. Henderson, John F. Glenn, Gregory J. Davenport, Martin J. J. Ronis, Peter J. Winsauer

PMC · DOI: 10.3389/ebm.2025.10356 · Experimental Biology and Medicine · 2025-05-19

## TL;DR

A cannabis-derived mixture given to mice did not cause liver damage or worsen liver disease linked to metabolic dysfunction.

## Contribution

Demonstrates that a cannabis mixture at antihyperalgesic doses does not worsen MASH in mice.

## Key findings

- Chronic administration of NEPE14 did not cause hepatotoxicity in mice on a control diet.
- NEPE14 did not significantly exacerbate MASH in mice fed a Western diet.
- No protective effect of NEPE14 against MASH was observed.

## Abstract

Cannabis and cannabinoid mixtures have been linked to a variety of health benefits including pain mitigation, suppression of nausea produced by chemotherapeutic agents, anti-inflammatory effects, and effects on energy homeostasis, glucose, and lipid metabolism. The latter properties have led to the suggestion that these products could have therapeutic effects on the development of metabolic dysfunction-associated steatohepatitis (MASH) - a severe type of liver pathology in obese and diabetic patients. However, varying agonist and antagonistic properties of different cannabinoids on the endogenous cannabinoid system make prediction regarding hepatic effects and diet interactions difficult. The current study was designed to examine hepatic pathology following chronic administration of a cannabinoid mixture (NEPE14) at a dose equivalent to one previously demonstrating antihyperalgesic effects in rats. The effects of NEPE14 were investigated in a mouse model of MASH produced by feeding a Western diet rich in fat and simple sugars. After 24 weeks of NEPE14 administration, there was no hepatotoxicity in mice receiving the control diet and no significant exacerbation of MASH in mice receiving the Western diet. In conclusion, no chronic liver toxicity was observed, but there was also no evidence for protection against MASH by this product.

## Linked entities

- **Diseases:** metabolic dysfunction-associated steatohepatitis (MONDO:0007027), MASH (MONDO:0007027)

## Full-text entities

- **Diseases:** diabetic (MESH:D003920), obese (MESH:D009765), liver toxicity (MESH:D056486), hepatic pathology (MESH:D005598), MASH (MESH:D005234), pain (MESH:D010146), nausea (MESH:D009325), inflammatory (MESH:D007249)
- **Chemicals:** cannabinoid (MESH:D002186), lipid (MESH:D008055), NEPE14 (-), glucose (MESH:D005947), sugars (MESH:D000073893)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12127212/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12127212/full.md

## References

31 references — full list in the complete paper: https://tomesphere.com/paper/PMC12127212/full.md

---
Source: https://tomesphere.com/paper/PMC12127212